Table 3.

Age and marker distributions for 399 benign patients (differentiated by benign stages)

Median (10th, 90th percentile) (range)Benign subtypes (n = 399)
Age (y)*Afamin (mg/L), P = 0.06ApoA-IV (mg/dL), P = 0.06CA125 (units/mL)*
Cervical dysplasia (n = 37)37.2 (25.9-69.9) (19.6-85.2)68.3 (43.3-93.1) (20.2-109.2)13.7 (5.2-16.9) (4.1-22.1)13.5 (9.0-43.6) (3.3-381.0)
Cystoma (n = 19)57.0 (37.2-67.7) (25.3-81.4)62.9 (48.4-93.6) (47.9-206.6)9.8 (6.5-18.4) (5.4-20.4)25.9 (12.5-81.6) (10.4-184.0)
Inflammation (n = 10)44.0 (27.2-71.8) (23.9-73.7)72.8 (34.5-86.2) (28.1-91.6)7.6 (4.2-13.6) (3.7-21.5)60.0 (8.4-47.0) (4.9-232.0)
Bleeding disorder (n = 32)51.1 (34.8-72.1) (20.4-84.6)62.2 (43.0-90.9) (41.2-120.6)11.8 (6.4-17.1) (4.1-22.9)12.9 (8.4-47.0) (4.9-232.0)
Uterus myomatosus (n = 67)43.1 (33.1-66.8) (21.6-75.7)64.0 (50.7-86.2) (44.5-103.6)11.3 (6.5-18.1) (2.0-20.3)18.1 (8.8-73.2) (4.0-157.0)
Ovarian cyst (n = 115)46.5 (25.9-73.7) (20.0-84.4)69.1 (51.4-98.4) (32.7-130.0)11.7 (7.9-20.3) (3.1-32.3)14.7 (7.4-52.2) (5.0-1,026.0)
Endometriosis (n = 41)36.2 (26.3-51.5) (21.7-75.0)58.8 (48.5-79.5) (28.0-94.0)11.4 (5.0-20.6) (2.3-28.6)34.9 (11.0-125.0) (8.1-371.0)
Benign adnex tumor (n = 45)48.6 (26.0-74.3) (18.5-84.1)68.5 (52.2-90.5) (39.3-127.2)11.1 (7.6-16.2) (3.3-20.6)19.8 (9.4-104.9) (4.1-293.0)
Nonmalignant unclear lower abdominal pain (n = 33)45.9 (25.7-69.5) (23.5-79.3)65.0 (50.6-88.2) (35.0-135.6)13.2 (8.5-19.6) (2.2-31.4)12.0 (5.4-29.6) (4.3-122.0)
  • * P < 0.0001 for difference among all subtypes (ANOVA).